Case report: Acamprosate for treatment of volatile hydrocarbon (VHC) inhalant use disorder with comorbid alcohol use disorder
Mental Health Clinician · 2026-06 · 16 (3) · 159-162
DOI: 10.9740/mhc.2026.06.159 ↗Kurz gefasst
Fallbericht in der Zeitschrift Mental Health Clinician, 2026-06. Verfasst von Nariman Piri und 1 weiteren Autor:innen. Beteiligte Einrichtung: (Corresponding author) Inpatient Psychiatric Pharmacist, Sutter Health Alta Bates Medical Center - Herrick Campus, Berkeley, California, npiri.mail@g…. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Introduction
Inhalant use disorder is a substance use disorder that involves the inhalation of volatile hydrocarbons (VHCs) to experience intoxication. Despite its prevalence and potential for adverse events, pharmacotherapy research for inhalant use disorder is limited. Acamprosate is a medication used for alcohol use disorder (AUD) that may provide benefit for inhalant use disorder. Acamprosate, alcohol, and inhalants all modulate glutamatergic and GABAergic pathways to produce their effects. Reported is a case of inhalant use disorder with comorbid AUD treated successfully with acamprosate. Case Report Patient A is a 39-year-old male consuming 16 cans of computer duster per day, having escalated use over the course of 2 weeks following a period of sobriety. He has been abstaining from alcohol with the help of disulfiram therapy. Following medical management, chronic inhalant use disorder pharmacotherapy was established with acamprosate 666 mg twice a day and later increased to 999 mg twice a day.
Discussion
Similarities in effect may lead to the comorbid use pattern of inhalants and alcohol for our patient. As disulfiram did not address the inhalant use, acamprosate was chosen in hopes of reducing cravings and encouraging abstinence in the long term.
Conclusion
Inhalant use disorder represents an understudied substance use disorder, and acamprosate may be a promising medication to investigate for broader safety and efficacy. Patients with comorbid AUD may be an especially likely population to benefit from acamprosate therapy due to the possibility of dual benefit from the FDA-approved AUD indication.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- (Corresponding author) Inpatient Psychiatric Pharmacist, Sutter Health Alta Bates Medical Center - Herrick Campus, Berkeley, California, npiri.mail@gmail.com.
- Inpatient Psychiatric Pharmacist, Raymond G. Murphy Medical Center of the New Mexico VA Health Care system, Albuquerque, New Mexico.
ORCID-Profile: Nariman Piri, Wesley Campbell
Zitieren
APA
Piri, N., & Campbell, W. (2026). Case report: Acamprosate for treatment of volatile hydrocarbon (VHC) inhalant use disorder with comorbid alcohol use disorder. Mental Health Clinician, 16(3), 159-162. https://doi.org/10.9740/mhc.2026.06.159
Vancouver
Piri N, Campbell W. Case report: Acamprosate for treatment of volatile hydrocarbon (VHC) inhalant use disorder with comorbid alcohol use disorder. Mental Health Clinician. 2026;16(3):159-162. doi:10.9740/mhc.2026.06.159
BibTeX
@article{Piri2026,
author = {Piri, Nariman and Campbell, Wesley},
title = {Case report: Acamprosate for treatment of volatile hydrocarbon (VHC) inhalant use disorder with comorbid alcohol use disorder},
journal = {Mental Health Clinician},
year = {2026},
volume = {16},
number = {3},
pages = {159--162},
doi = {10.9740/mhc.2026.06.159}
}
EUVIMED